Teleflex Incorporated Company Profile (NYSE:TFX)

Teleflex Incorporated trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."

Teleflex Incorporated declared a quarterly dividend on Monday, May 8th. Stockholders of record on Monday, May 15th will be given a dividend of $0.34 per share on Thursday, June 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date of this dividend is Thursday, May 11th. View Teleflex Incorporated's Dividend History.

Teleflex Incorporated (NYSE:TFX) released its quarterly earnings results on Thursday, May, 4th. The company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.69 by $0.11. The company had revenue of $487.90 million for the quarter, compared to analysts' expectations of $472.81 million. Teleflex Incorporated had a net margin of 11.75% and a return on equity of 16.17%. Teleflex Incorporated's quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.52 earnings per share. View Teleflex Incorporated's Earnings History.

Teleflex Incorporated is scheduled to release their next quarterly earnings announcement on Thursday, August, 3rd 2017. View Earnings Estimates for Teleflex Incorporated.

Teleflex Incorporated updated its FY17 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of $8.05-8.23 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.10.

6 equities research analysts have issued 1-year price objectives for Teleflex Incorporated's stock. Their predictions range from $205.00 to $224.00. On average, they expect Teleflex Incorporated's share price to reach $214.80 in the next twelve months. View Analyst Ratings for Teleflex Incorporated.

Here are some recent quotes from research analysts about Teleflex Incorporated stock:

• 1. Barclays PLC analysts commented, "Epizyme, Inc. announced today that it has expanded its clinical collaboration with Genentech, a member of the Roche Group. Under the new agreement, Tazemetostat administered in combination with atezolizumab (Tecentriq) will be evaluated in a phase Ib/II clinical study for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer (NSCLC)." (6/26/2017)
• 2. According to Zacks Investment Research, "Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. " (6/23/2017)
• 3. Needham & Company LLC analysts commented, "TFX’s 1Q17 revenue and EPS beat consensus. Management maintained its 2017 revenue guidance and raised its 2017 EPS guidance. TFX’s organic revenue growth slowed to 4.2% in 1Q17 from 6.5% in 4Q16. Importantly, Vascular Solutions saw its momentum continue despite the acquisition with growth of 13%. TFX’s had strong margin performance with its gross margin up 110 bps Y/Y and its operating margin up 100 bps Y/Y." (5/5/2017)
• 4. Deutsche Bank AG analysts commented, "TFX shares recovered since last October when mgmt lowered its sales forecast last recently reaching an all-time high. In our view, the question for investors is "where do we go from here?" We believe 2017 sales guidance was set appropriately. We see some opportunities for EPS upside given our view that some conservatism may be built into and TFX's track record of solid execution on M&A integration. Mgmt plans on hosting an investor day in Sept to provide LT guidance. We continue to see sales acceleration, gross and op margin expansion. While shares are unlikely to make the same significant price moves similar to the past four months, we still see some upside." (3/15/2017)

Some companies that are related to Teleflex Incorporated include Laboratory Corporation of America Holdings (LH), Smith & Nephew SNATS (SNN), Eisai Co., Ltd (ESALY), BioMarin Pharmaceutical (BMRN), Quest Diagnostics Incorporated (DGX), Henry Schein (HSIC), IDEXX Laboratories (IDXX), DENTSPLY SIRONA (XRAY), Centene Corporation (CNC), Genmab A/S (GNMSF), Lonza Group Ag (LZAGY), Align Technology (ALGN), DaVita HealthCare Partners (DVA), Olympus Corp. (OCPNY), Hologic (HOLX), Cooper Companies, Inc. (The) (COO), H. Lundbeck A/S- (HLUYY) and ResMed (RMD).

Teleflex Incorporated's management team includes the folowing people:

• Benson F. Smith, Non-Executive Chairman of the Board
• Liam J. Kelly, President, Chief Executive Officer
• Thomas E. Powell, Chief Financial Officer, Executive Vice President
• Thomas Anthony Kennedy, Senior Vice President - Global Operations
• John R. Deren, Chief Accounting Officer, Vice President
• James J. Leyden, Vice President, General Counsel, Secretary
• Karen T. Boylan, Vice President - Global RA/QA
• Cameron P. Hicks, Vice President - Global Human Resources
• Patricia C. Barron, Lead Independent Director
• Gretchen R. Haggerty, Director

Teleflex Incorporated's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (0.87%), Ardevora Asset Management LLP (0.39%), Rothschild Asset Management Inc. (0.33%), Copper Rock Capital Partners LLC (0.30%), Public Employees Retirement Association of Colorado (0.24%) and Mountain Pacific Investment Advisers Inc. ID (0.23%). Company insiders that own Teleflex Incorporated stock include Gretchen R Haggerty, Jeffrey A Graves, John Deren, Patricia C Barron, Stephen K MD Klasko, Stuart A Randle and Thomas Anthony Kennedy. View Institutional Ownership Trends for Teleflex Incorporated.

Teleflex Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Barometer Capital Management Inc., Acadian Asset Management LLC, Russell Investments Group Ltd., Tealwood Asset Management Inc., Buffington Mohr McNeal, Ardevora Asset Management LLP, Mountain Pacific Investment Advisers Inc. ID and Legacy Private Trust Co.. Company insiders that have sold Teleflex Incorporated stock in the last year include Jeffrey A Graves, John Deren, Stephen K MD Klasko and Stuart A Randle. View Insider Buying and Selling for Teleflex Incorporated.

Teleflex Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Rothschild Asset Management Inc., Mn Services Vermogensbeheer B.V., Denali Advisors LLC, Sheets Smith Wealth Management, Aperio Group LLC, Shell Asset Management Co. and Oakbrook Investments LLC. View Insider Buying and Selling for Teleflex Incorporated.

Shares of Teleflex Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Teleflex Incorporated stock can currently be purchased for approximately $210.42.